Review highlights advances in gold nanoparticles for brain delivery in CNS diseases, suggesting therapeutic potential.
Central nervous system (CNS) diseases, including neurodegenerative disorders and brain cancers, remain leading causes of disability and death, largely due to limited drug penetration across the blood-brain barrier (BBB). Gold nanoparticles (AuNPs) have emerged as versatile platforms for CNS applications, with tunable morphology, surface chemistry, and optical properties, enabling both therapeutic and diagnostic use. This review highlights recent advances in the design and optimization of AuNPs for brain-targeted delivery, explores their applications in CNS diseases, and discusses current challenges, safety considerations, and future prospects for clinical translation.
No takes yet. Share an insight, caveat, or question.
Han et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: